LONDON--Danish pharmaceutical company Novo Nordisk A/S (NOVO-B.KO) Friday said a trial of Saxenda showed treatment with the drug for three years reduced the risk of developing type 2 diabetes compared with a placebo.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novo Nordisk Charts.